Mizuho Markets Americas LLC Has $21.49 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mizuho Markets Americas LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 14.3% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 375,446 shares of the biopharmaceutical company’s stock after selling 62,660 shares during the quarter. Mizuho Markets Americas LLC’s holdings in Halozyme Therapeutics were worth $21,491,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 254 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $33,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $49,000. Toth Financial Advisory Corp bought a new position in shares of Halozyme Therapeutics in the third quarter worth about $57,000. Finally, FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $65,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at $10,778,084.68. This trade represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last ninety days, insiders sold 70,000 shares of company stock worth $4,042,500. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

HALO stock opened at $45.65 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a twelve month low of $33.15 and a twelve month high of $65.53. The business’s fifty day moving average is $56.04 and its 200-day moving average is $53.27. The company has a market cap of $5.81 billion, a P/E ratio of 15.12, a price-to-earnings-growth ratio of 0.54 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. The Goldman Sachs Group upped their target price on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler upped their price target on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $61.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.